Technology Venture Partners appoints Richard Green as Non-executive Chairman

July 16th, 2015|

Technology Venture Partners the technology venture capital firm has announced the appointment of Richard Green as Non-executive Chairman.

Richard Green joined Kleinwort Benson Development Capital in 1988 and was a founder in 2001 of the spin-out business which became August Equity LLP, where he was the Managing Partner until 2009 and then Chairman until his retirement in April 2014.  He is a past chairman of the British Venture Capital Association and is currently a non-executive director of AIM-quoted Qannas Investments Limited, a non-executive director of Northern Venture Trust PLC, a member of the Advisory Board of Finance for Business North East and a member of the Advisory Committee of the European Investment Bank’s Growth Finance Initiative.

[Read More]

Symetrica Appoints David Price As Chairman

June 23rd, 2015|

Symetrica, the Technology Venture Partners portfolio company providing radiation detection solutions company has announced the appointment of David Price as Non-executive Chairman.

David Price was formerly CEO of Chemring Group plc, the FTSE 250 listed with revenues of £600m. Chemring is a specialist manufacturer of expendable countermeasures, advanced electronics and energetic materials for the global defence, security and safety markets. Prior to Chemring, David was MD of Rolls Royce Naval Marine, a division supplying propulsion systems, products & services to 59 navies for both submarine and surface ship applications. Naval Marine is a global business with a turnover of over £450m per year and employing 2900 staff. It undertook the design authority role for all Royal Navy nuclear reactor systems and manufactured all of the key components for the Pressurised Water Reactor.

[Read More]

Micrima’s radiowave breast cancer detection system gains EU regulatory approval

April 29th, 2015|

Micrima, the Bristol company developing a safe, low-cost way of improving breast cancer detection, has gained CE marking for its MARIA (Multistatic Array processing for Radiowave Image Acquisition) product, paving the way for further supportive clinical trials in the UK and expansion into Europe.

[Read More]

Atlas completes $20 million Series C fundraising

January 29th, 2015|

Funds to accelerate global launch of Atlas io® molecular testing system

Bath, UK, 29 January, 2015. Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces the completion of a Series C financing, raising $20 million from a syndicate including existing investors and one new investor, RMI Partners. New investor, RMI Partners, is a global life sciences venture capital firm, the largest in Eastern Europe. Existing investors include Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation – JJDC, Inc., LSP, BB Biotech Ventures and Technology Venture Partners. This newly announced financing follows on from the previously announced Series B fundraising of $25 million.

[Read More]